July 8, 2011 -- BeiGene, the Beijing area oncology startup, said it expects to raise between $100 million and $150 million this year from a group of up to seven biopharmas and venture capitalists. In May, the company announced it received backing from Merck, though it didn’t disclose the size of the financing. At the time, CEO John Oyler told ChinaBio® Today that the Merck financing did not prohibit BeiGene from seeking backing from other pharmas, an important provision. More details....
Stock Symbol: (NYSE: MRK)
